Altamira Therapeutics Ltd. Research And Development Expense

• Altamira Therapeutics Ltd. showed an increase of +10.3% in Research And Development Expense from 2023 to 2024.
• This data is from Altamira Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on April 30, 2025.
• XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2015 to 2024), Altamira Therapeutics Ltd.'s Research And Development Expense has declined by 86.0%.
• Historical annual values: Fiscal year 2024: $3.73 million | Fiscal year 2023: $3.38 million | Fiscal year 2022: $15.31 million | Fiscal year 2021: $3.20 million | Fiscal year 2020: $2.86 million | Fiscal year 2019: $3.33 million | Fiscal year 2018: $6.69 million | Fiscal year 2017: $19.21 million | Fiscal year 2016: $24.78 million | Fiscal year 2015: $26.54 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026